<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563313</url>
  </required_header>
  <id_info>
    <org_study_id>DCLP3</org_study_id>
    <secondary_id>UC4DK108483</secondary_id>
    <nct_id>NCT03563313</nct_id>
  </id_info>
  <brief_title>The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas</brief_title>
  <acronym>DCLP3</acronym>
  <official_title>A Pivotal Study of t:Slim X2 With Control-IQ Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tandem Diabetes Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess efficacy and safety of a closed loop system (t:slim
      X2 with Control-IQ Technology) in a large randomized controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After consent is signed, eligibility will be assessed. Eligible participants not currently
      using an insulin pump and Dexcom CGM with minimum data requirements will initiate a run-in
      phase of 2 to 8 weeks that will be customized based on whether the participant is already a
      pump or CGM user. Participants who skip or successfully complete the run-in will be randomly
      assigned 2:1 to the use of closed-loop control (CLC group) using t:slim X2 with Control-IQ
      Technology vs. SAP for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Actual">April 8, 2019</completion_date>
  <primary_completion_date type="Actual">April 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized controlled trial of 6 month at home closed loop system vs. sensor-augmented pump.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in Target Range</measure>
    <time_frame>26 weeks</time_frame>
    <description>The primary outcome is time in target range 70-180 mg/dL measured by CGM in CLC group vs. SAP group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGM Time Above 180</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM-measured % above 180 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Mean Glucose</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM-measured mean glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at 26 Weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>Hemoglobin A1c measured at 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Time Below 70</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM-measured % below 70 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Time Below 54</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM-measured % below 54 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Time in Range 70-140 mg/dL</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM-measured % in range 70-140 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of Variability</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM measured glucose variability measured with the coefficient of variation (CV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Deviation of CGM</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM measured glucose variability measured with the standard deviation (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Time Below 60</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM-measured % below 60 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LBGI</measure>
    <time_frame>26 weeks</time_frame>
    <description>Low blood glucose index by CGM with higher index indicating higher risk of hypoglycemia. Values &lt;1 suggest minimal risk. Index of risk of low blood glucose excursion based on a standard formula for non-linear transformation of the blood glucose scale (Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke WL: Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 21:1870-1875, 1998)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Hypoglycemia Events</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM-measured events of at least 15 consecutive minutes &lt;70mg/dL per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Time &gt;250</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM-measured % &gt;250 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Time &gt;300</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM-measured % &gt;300 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBGI</measure>
    <time_frame>26 weeks</time_frame>
    <description>High blood glucose index by CGM with higher values indicating higher risk of hyperglycemia. Index of risk of high blood glucose excursion based on a standard formula for non-linear transformation of the blood glucose scale (Kovatchev BP, Cox DJ, Kumar A, Gonder-Frederick L, Clarke WL. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 2003;5:817-828pmid:14633347)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HbA1c &lt;7.0% at 26 Weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of participants HbA1c &lt;7.0% at 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HbA1c &lt;7.5% at 26 Weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of Participants with HbA1c &lt;7.5% at 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HbA1c Improvement From Baseline to 26 Weeks &gt;0.5%</measure>
    <time_frame>26 weeks</time_frame>
    <description>HbA1c improvement from baseline to 26 weeks &gt;0.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HbA1c Improvement From Baseline to 26 Weeks &gt;1.0%</measure>
    <time_frame>26 weeks</time_frame>
    <description>HbA1c improvement from baseline to 26 weeks &gt;1.0%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Relative Improvement From Baseline to 26 Weeks &gt;10%</measure>
    <time_frame>26 weeks</time_frame>
    <description>HbA1c relative improvement from baseline to 26 weeks &gt;10%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HbA1c Improvement From Baseline to 26 Weeks &gt;1.0% or HbA1c &lt;7.0% at 26 Weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>HbA1c improvement from baseline to 26 weeks &gt;1.0% or HbA1c &lt;7.0% at 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HFS-II</measure>
    <time_frame>26 weeks</time_frame>
    <description>For adults, teens and parents items on this survey are rated on a 5 point Likert scale from never (0) to almost always (4). The survey is scored by summing item responses. Fear of Hypoglycemia Survey (HFS-II) for adults has a total score that is summed from the two subscale scores (33 items) and ranges from 0 to 132 with higher scores indicating greater degrees of fear of hypoglycemia. The teen survey has a total of 25 items and the range of Total scores is 0 to 100. The parent version of the survey has a total of 26 items with Total scores that range from 0 to 108.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperglycemia Avoidance Scale</measure>
    <time_frame>26 weeks</time_frame>
    <description>Hyperglycemia Avoidance Scale total score is the sum of 21 items rated on a 4 point Likert scale from 0 (never) to 4 (almost always) and ranges from 0 to 84 with a higher score indicating greater degrees of avoiding hyperglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Distress Scale</measure>
    <time_frame>26 weeks</time_frame>
    <description>Diabetes Distress Scale for adults has 28 items rated on a 6 point Likert scale that ranges from 1 (not a problem) to 6 (a very serious problem). The total score is the mean of the sum of responses and ranges from 1 to 6 where a higher score indicates greater degrees of diabetes distress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia Confidence Scale</measure>
    <time_frame>26 weeks</time_frame>
    <description>Hypoglycemia Confidence Scale has 20 items which are rated on a 4-point Likert Scale ranging from 1 (not confident at all) to 4 (very confident) with higher scores indicating higher confidence in dealing with hypoglycemia. A single score is computed by calculating the mean of the sum of all items and ranges from 1 to 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clarke Hypoglycemia Awareness Scores</measure>
    <time_frame>26 weeks</time_frame>
    <description>Clarke Hypoglycemia Awareness Scores (0-7 score with higher scores associated with impaired awareness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INSPIRE Survey Scores</measure>
    <time_frame>26 weeks</time_frame>
    <description>The INSPIRE questionnaire assesses user expectations and experiences with Insulin Delivery Systems: Perceptions, Ideas, Reflections, Expectations (INSPIRE). Survey total scores are computed by calculating the mean of the sum of all item ratings then multiplying the mean by 25 to scale the score to a range from 0 to 100. Higher scores indicate a more positive perception of insulin delivery systems. Items are rated on a 5 point Likert scale ranging from 0 (strongly disagree) to 4 (strongly agree). The Adult survey has 22 items, the Teens/Adolescents survey has 17 items and the Parent survey has 21 items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>System Usability Scores (SUS)</measure>
    <time_frame>26 weeks</time_frame>
    <description>System Usability Scores (SUS)-composite score from 0 to 100 with higher scores indicate better perceived usability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technology Acceptance Questionnaire</measure>
    <time_frame>26 weeks</time_frame>
    <description>Technology Acceptance Survey measures the user's perceptions regarding the burdens and the barriers associated with a technology with a higher score indicates increased technology acceptance. There total score uses 37 items with items are rated on a 5 point scale ranging from 1 (strongly disagree) to 5 (strongly agree) for total score range of 37-185.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Insulin</measure>
    <time_frame>26 weeks</time_frame>
    <description>Total Daily Insulin (units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal:Bolus Insulin Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Basal:Bolus Insulin Ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>26 weeks</time_frame>
    <description>Weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>26 weeks</time_frame>
    <description>Body Mass Index (BMI) kg/m^2</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Severe Hypoglycemia (Per Protocol)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Severe hypoglycemia (per protocol)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Diabetic Ketoacidosis (Per Protocol)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Diabetic ketoacidosis (per protocol)</description>
  </other_outcome>
  <other_outcome>
    <measure>Ketone Events Defined as Day With Ketone Level &gt;1.0 mmol/L</measure>
    <time_frame>26 weeks</time_frame>
    <description>Ketone events defined as day with ketone level &gt;1.0 mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>CGM-measured Hypoglycemic Events (&gt;15 Minutes With Glucose Concentration &lt;54 mg/dL)</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM-measured hypoglycemic events (&gt;15 minutes with glucose concentration &lt;54 mg/dL)</description>
  </other_outcome>
  <other_outcome>
    <measure>CGM-measured Hyperglycemic Events (&gt;15 Minutes With Glucose Concentration &gt;300 mg/dL)</measure>
    <time_frame>26 weeks</time_frame>
    <description>CGM-measured hyperglycemic events (&gt;15 minutes with glucose concentration &gt;300 mg/dL)</description>
  </other_outcome>
  <other_outcome>
    <measure>BG-measured Hypoglycemic Events (One BG Record &lt;54 mg/dL)</measure>
    <time_frame>26 weeks</time_frame>
    <description>BG-measured hypoglycemic events (one BG record &lt;54 mg/dL)</description>
  </other_outcome>
  <other_outcome>
    <measure>BG-measured Hyperglycemic Events (One BG Record &gt;350 mg/dL)</measure>
    <time_frame>26 weeks</time_frame>
    <description>BG-measured hyperglycemic events (one BG record &gt;350 mg/dL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Worsening of HbA1c From Baseline to 26 Weeks by &gt;0.5%</measure>
    <time_frame>26 weeks</time_frame>
    <description>Worsening of HbA1c from baseline to 26 weeks by &gt;0.5%</description>
  </other_outcome>
  <other_outcome>
    <measure>Other Serious Adverse Events (SAE) and Serious Adverse Device Events (SADE)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Other serious adverse events (SAE) and serious adverse device events (SADE)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Device Effects (ADE)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Adverse device effects (ADE)</description>
  </other_outcome>
  <other_outcome>
    <measure>Unanticipated Adverse Device Effects (UADE)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Unanticipated adverse device effects (UADE)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With SH Events</measure>
    <time_frame>26 weeks</time_frame>
    <description>For this outcome, mean +/- SD or summary statistics appropriate to the distribution will be tabulated by treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>SH Event Rate Per 100 Person-years</measure>
    <time_frame>26 weeks</time_frame>
    <description>For this outcome, severe hypoglycemia event rate per 100 person-years will be calculated as a rate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With DKA Events</measure>
    <time_frame>26 weeks</time_frame>
    <description>For this outcome, number of participants with diabetic ketoacidosis (DKA) will be tabulated.</description>
  </other_outcome>
  <other_outcome>
    <measure>DKA Event Rate Per 100 Person-years</measure>
    <time_frame>26 weeks</time_frame>
    <description>For this outcome, the diabetic ketoacidosis event rate per 100 person-years will be calculated as a rate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Any Adverse Event Rate Per 100 Person-years</measure>
    <time_frame>26 weeks</time_frame>
    <description>For this outcome, the adverse event rate per 100 person-years calculated as a rate.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Closed Loop Control (CLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sensor-Augmented Pump (SAP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM</intervention_name>
    <description>Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
    <arm_group_label>Closed Loop Control (CLC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sensor-augmented pump (SAP)</intervention_name>
    <description>Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
    <arm_group_label>Sensor-Augmented Pump (SAP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
             one year and using insulin for at least 1 year.

          2. Familiarity and use of a carbohydrate ratio for meal boluses.

          3. Age ≥14.0 years old.

          4. For females, not currently known to be pregnant. If female and sexually active, must
             agree to use a form of contraception to prevent pregnancy while a participant in the
             study. A negative serum or urine pregnancy test will be required for all females of
             child-bearing potential. Participants who become pregnant will be discontinued from
             the study. Also, participants who during the study develop and express the intention
             to become pregnant within the timespan of the study will be discontinued.

          5. For participants &lt;18 years old, living with one or more parent/legal guardian
             knowledgeable about emergency procedures for severe hypoglycemia and able to contact
             the participant in case of an emergency.

          6. Willingness to suspend use of any personal CGM for the duration of the clinical trial
             once the study CGM is in use.

          7. Willingness to use a regular insulin pump during the study with no automatic insulin
             adjustment based on glucose level when assigned to participate in an SAP group

          8. Investigator has confidence that the participant can successfully operate all study
             devices and is capable of adhering to the protocol.

          9. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already,
             and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the
             study.

         10. Total daily insulin dose (TDD) at least 10 U/day.

         11. Willingness not to start any new non-insulin glucose-lowering agent during the course
             of the trial.

        Exclusion Criteria

          1. Concurrent use of any non-insulin glucose-lowering agent other than metformin
             (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors,
             sulfonylureas).

          2. Hemophilia or any other bleeding disorder.

          3. A condition, which in the opinion of the investigator or designee, would put the
             participant or study at risk.

          4. Participation in another pharmaceutical or device trial at the time of enrollment or
             during the study.

          5. Employed by, or having immediate family members employed by Tandem Diabetes Care, Inc.
             or TypeZero Technologies, LLC, or having a direct supervisor at place of employment
             who is also directly involved in conducting the clinical trial (as a study
             investigator, coordinator, etc.); or having a first-degree relative who is directly
             involved in conducting the clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue A. Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sansum Diabetes Research Institute</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center, University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard University (Joslin Diabetes Center)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Center for Diabetes Technology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <results_first_submitted>March 31, 2020</results_first_submitted>
  <results_first_submitted_qc>March 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2020</results_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Sue Brown</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Artificial Pancreas (AP)</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Insulin Pump</keyword>
  <keyword>Continuous Glucose Monitor (CGM)</keyword>
  <keyword>Closed Loop Control (CLC)</keyword>
  <keyword>Sensor-Augmented Pump (SAP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will follow the NIH Data Sharing Policy and Implementation Guidance on sharing research resources for research purposes to qualified individuals within the scientific community.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Generally, data will be made available after the primary publications of each study.</ipd_time_frame>
    <ipd_access_criteria>The Data Sharing Agreements will be formulated by the Steering Committee in collaboration with the NIH Project Scientist Program Official.
In addition, under special arrangements, complete data sets will be provided to industry partners who would use the data for regulatory clearance (PMA - pre-market approval) of the tested artificial pancreas system. This will be done in response to the specific requirements of RFA-DK-14-024 for this project to &quot;…generate data able to satisfy safety and efficacy requirements by regulatory agencies regarding the clinical testing of artificial pancreas device systems&quot; in the target population of people with type 1 diabetes.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03563313/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03563313/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03563313/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Closed Loop Control (CLC)</title>
          <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
        </group>
        <group group_id="P2">
          <title>Sensor-Augmented Pump (SAP)</title>
          <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Closed Loop Control (CLC)</title>
          <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
        </group>
        <group group_id="B2">
          <title>Sensor-Augmented Pump (SAP)</title>
          <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="112"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="16"/>
                    <measurement group_id="B2" value="33" spread="17"/>
                    <measurement group_id="B3" value="33" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CGM Time in Target Range 70-180 mg/dL</title>
          <description>CGM percentage of time in target range measured over 2-week baseline.</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="17"/>
                    <measurement group_id="B2" value="59" spread="14"/>
                    <measurement group_id="B3" value="60" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time in Target Range</title>
        <description>The primary outcome is time in target range 70-180 mg/dL measured by CGM in CLC group vs. SAP group.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Target Range</title>
          <description>The primary outcome is time in target range 70-180 mg/dL measured by CGM in CLC group vs. SAP group.</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="12"/>
                    <measurement group_id="O2" value="59" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Time Above 180</title>
        <description>CGM-measured % above 180 mg/dL</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Time Above 180</title>
          <description>CGM-measured % above 180 mg/dL</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="12"/>
                    <measurement group_id="O2" value="38" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Mean Glucose</title>
        <description>CGM-measured mean glucose</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Mean Glucose</title>
          <description>CGM-measured mean glucose</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156" spread="19"/>
                    <measurement group_id="O2" value="170" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c at 26 Weeks</title>
        <description>Hemoglobin A1c measured at 26 weeks</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c at 26 Weeks</title>
          <description>Hemoglobin A1c measured at 26 weeks</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06" spread="0.79"/>
                    <measurement group_id="O2" value="7.39" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Time Below 70</title>
        <description>CGM-measured % below 70 mg/dL</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Time Below 70</title>
          <description>CGM-measured % below 70 mg/dL</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="1.15"/>
                    <measurement group_id="O2" value="2.25" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Time Below 54</title>
        <description>CGM-measured % below 54 mg/dL</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Time Below 54</title>
          <description>CGM-measured % below 54 mg/dL</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.29"/>
                    <measurement group_id="O2" value="0.35" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Time in Range 70-140 mg/dL</title>
        <description>CGM-measured % in range 70-140 mg/dL</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Time in Range 70-140 mg/dL</title>
          <description>CGM-measured % in range 70-140 mg/dL</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="12"/>
                    <measurement group_id="O2" value="36" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coefficient of Variability</title>
        <description>CGM measured glucose variability measured with the coefficient of variation (CV)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Coefficient of Variability</title>
          <description>CGM measured glucose variability measured with the coefficient of variation (CV)</description>
          <units>percentage SD of Mean</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" spread="5"/>
                    <measurement group_id="O2" value="36" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standard Deviation of CGM</title>
        <description>CGM measured glucose variability measured with the standard deviation (SD)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Standard Deviation of CGM</title>
          <description>CGM measured glucose variability measured with the standard deviation (SD)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" spread="12"/>
                    <measurement group_id="O2" value="62" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Time Below 60</title>
        <description>CGM-measured % below 60 mg/dL</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Time Below 60</title>
          <description>CGM-measured % below 60 mg/dL</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.52"/>
                    <measurement group_id="O2" value="0.75" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LBGI</title>
        <description>Low blood glucose index by CGM with higher index indicating higher risk of hypoglycemia. Values &lt;1 suggest minimal risk. Index of risk of low blood glucose excursion based on a standard formula for non-linear transformation of the blood glucose scale (Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke WL: Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 21:1870-1875, 1998)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>LBGI</title>
          <description>Low blood glucose index by CGM with higher index indicating higher risk of hypoglycemia. Values &lt;1 suggest minimal risk. Index of risk of low blood glucose excursion based on a standard formula for non-linear transformation of the blood glucose scale (Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke WL: Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 21:1870-1875, 1998)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.29"/>
                    <measurement group_id="O2" value="0.65" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Hypoglycemia Events</title>
        <description>CGM-measured events of at least 15 consecutive minutes &lt;70mg/dL per week</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Hypoglycemia Events</title>
          <description>CGM-measured events of at least 15 consecutive minutes &lt;70mg/dL per week</description>
          <units>events per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.1"/>
                    <measurement group_id="O2" value="4.3" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Time &gt;250</title>
        <description>CGM-measured % &gt;250 mg/dL</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Time &gt;250</title>
          <description>CGM-measured % &gt;250 mg/dL</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="6.7"/>
                    <measurement group_id="O2" value="12.3" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Time &gt;300</title>
        <description>CGM-measured % &gt;300 mg/dL</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Time &gt;300</title>
          <description>CGM-measured % &gt;300 mg/dL</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="3.4"/>
                    <measurement group_id="O2" value="4.6" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBGI</title>
        <description>High blood glucose index by CGM with higher values indicating higher risk of hyperglycemia. Index of risk of high blood glucose excursion based on a standard formula for non-linear transformation of the blood glucose scale (Kovatchev BP, Cox DJ, Kumar A, Gonder-Frederick L, Clarke WL. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 2003;5:817-828pmid:14633347)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>HBGI</title>
          <description>High blood glucose index by CGM with higher values indicating higher risk of hyperglycemia. Index of risk of high blood glucose excursion based on a standard formula for non-linear transformation of the blood glucose scale (Kovatchev BP, Cox DJ, Kumar A, Gonder-Frederick L, Clarke WL. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 2003;5:817-828pmid:14633347)</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="3.1"/>
                    <measurement group_id="O2" value="9.0" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HbA1c &lt;7.0% at 26 Weeks</title>
        <description>Number of participants HbA1c &lt;7.0% at 26 weeks</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HbA1c &lt;7.0% at 26 Weeks</title>
          <description>Number of participants HbA1c &lt;7.0% at 26 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HbA1c &lt;7.5% at 26 Weeks</title>
        <description>Number of Participants with HbA1c &lt;7.5% at 26 weeks</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HbA1c &lt;7.5% at 26 Weeks</title>
          <description>Number of Participants with HbA1c &lt;7.5% at 26 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HbA1c Improvement From Baseline to 26 Weeks &gt;0.5%</title>
        <description>HbA1c improvement from baseline to 26 weeks &gt;0.5%</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HbA1c Improvement From Baseline to 26 Weeks &gt;0.5%</title>
          <description>HbA1c improvement from baseline to 26 weeks &gt;0.5%</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HbA1c Improvement From Baseline to 26 Weeks &gt;1.0%</title>
        <description>HbA1c improvement from baseline to 26 weeks &gt;1.0%</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HbA1c Improvement From Baseline to 26 Weeks &gt;1.0%</title>
          <description>HbA1c improvement from baseline to 26 weeks &gt;1.0%</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Relative Improvement From Baseline to 26 Weeks &gt;10%</title>
        <description>HbA1c relative improvement from baseline to 26 weeks &gt;10%</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Relative Improvement From Baseline to 26 Weeks &gt;10%</title>
          <description>HbA1c relative improvement from baseline to 26 weeks &gt;10%</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="19"/>
                    <measurement group_id="O2" value="2" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HbA1c Improvement From Baseline to 26 Weeks &gt;1.0% or HbA1c &lt;7.0% at 26 Weeks</title>
        <description>HbA1c improvement from baseline to 26 weeks &gt;1.0% or HbA1c &lt;7.0% at 26 weeks</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HbA1c Improvement From Baseline to 26 Weeks &gt;1.0% or HbA1c &lt;7.0% at 26 Weeks</title>
          <description>HbA1c improvement from baseline to 26 weeks &gt;1.0% or HbA1c &lt;7.0% at 26 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HFS-II</title>
        <description>For adults, teens and parents items on this survey are rated on a 5 point Likert scale from never (0) to almost always (4). The survey is scored by summing item responses. Fear of Hypoglycemia Survey (HFS-II) for adults has a total score that is summed from the two subscale scores (33 items) and ranges from 0 to 132 with higher scores indicating greater degrees of fear of hypoglycemia. The teen survey has a total of 25 items and the range of Total scores is 0 to 100. The parent version of the survey has a total of 26 items with Total scores that range from 0 to 108.</description>
        <time_frame>26 weeks</time_frame>
        <population>Total Score at 26 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC) in Adults</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP) in Adults</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
          <group group_id="O3">
            <title>CLC in Teens</title>
            <description>Survey response from a teen in CLC (14-18 years old)</description>
          </group>
          <group group_id="O4">
            <title>SAP in Teens</title>
            <description>Survey response from a Teen in the SAP group (ages 14-18).</description>
          </group>
          <group group_id="O5">
            <title>Parent of Teen in CLC</title>
            <description>Survey response from a parent of a teen in CLC</description>
          </group>
          <group group_id="O6">
            <title>Parent of a Teen in SAP</title>
            <description>Survey response from a parent of a teen in SAP</description>
          </group>
        </group_list>
        <measure>
          <title>HFS-II</title>
          <description>For adults, teens and parents items on this survey are rated on a 5 point Likert scale from never (0) to almost always (4). The survey is scored by summing item responses. Fear of Hypoglycemia Survey (HFS-II) for adults has a total score that is summed from the two subscale scores (33 items) and ranges from 0 to 132 with higher scores indicating greater degrees of fear of hypoglycemia. The teen survey has a total of 25 items and the range of Total scores is 0 to 100. The parent version of the survey has a total of 26 items with Total scores that range from 0 to 108.</description>
          <population>Total Score at 26 weeks</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="12"/>
                    <measurement group_id="O2" value="38" spread="18"/>
                    <measurement group_id="O3" value="32" spread="10"/>
                    <measurement group_id="O4" value="31" spread="16"/>
                    <measurement group_id="O5" value="33" spread="14"/>
                    <measurement group_id="O6" value="36" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hyperglycemia Avoidance Scale</title>
        <description>Hyperglycemia Avoidance Scale total score is the sum of 21 items rated on a 4 point Likert scale from 0 (never) to 4 (almost always) and ranges from 0 to 84 with a higher score indicating greater degrees of avoiding hyperglycemia.</description>
        <time_frame>26 weeks</time_frame>
        <population>Total Score at 26 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Hyperglycemia Avoidance Scale</title>
          <description>Hyperglycemia Avoidance Scale total score is the sum of 21 items rated on a 4 point Likert scale from 0 (never) to 4 (almost always) and ranges from 0 to 84 with a higher score indicating greater degrees of avoiding hyperglycemia.</description>
          <population>Total Score at 26 weeks</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="7"/>
                    <measurement group_id="O2" value="37" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diabetes Distress Scale</title>
        <description>Diabetes Distress Scale for adults has 28 items rated on a 6 point Likert scale that ranges from 1 (not a problem) to 6 (a very serious problem). The total score is the mean of the sum of responses and ranges from 1 to 6 where a higher score indicates greater degrees of diabetes distress.</description>
        <time_frame>26 weeks</time_frame>
        <population>Total Score at 26 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Diabetes Distress Scale</title>
          <description>Diabetes Distress Scale for adults has 28 items rated on a 6 point Likert scale that ranges from 1 (not a problem) to 6 (a very serious problem). The total score is the mean of the sum of responses and ranges from 1 to 6 where a higher score indicates greater degrees of diabetes distress.</description>
          <population>Total Score at 26 weeks</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.6"/>
                    <measurement group_id="O2" value="1.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemia Confidence Scale</title>
        <description>Hypoglycemia Confidence Scale has 20 items which are rated on a 4-point Likert Scale ranging from 1 (not confident at all) to 4 (very confident) with higher scores indicating higher confidence in dealing with hypoglycemia. A single score is computed by calculating the mean of the sum of all items and ranges from 1 to 4.</description>
        <time_frame>26 weeks</time_frame>
        <population>First two items on hypoglycemia confidence scale</population>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC) in Adults</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP) in Adults</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia Confidence Scale</title>
          <description>Hypoglycemia Confidence Scale has 20 items which are rated on a 4-point Likert Scale ranging from 1 (not confident at all) to 4 (very confident) with higher scores indicating higher confidence in dealing with hypoglycemia. A single score is computed by calculating the mean of the sum of all items and ranges from 1 to 4.</description>
          <population>First two items on hypoglycemia confidence scale</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Execise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleeping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clarke Hypoglycemia Awareness Scores</title>
        <description>Clarke Hypoglycemia Awareness Scores (0-7 score with higher scores associated with impaired awareness)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Clarke Hypoglycemia Awareness Scores</title>
          <description>Clarke Hypoglycemia Awareness Scores (0-7 score with higher scores associated with impaired awareness)</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INSPIRE Survey Scores</title>
        <description>The INSPIRE questionnaire assesses user expectations and experiences with Insulin Delivery Systems: Perceptions, Ideas, Reflections, Expectations (INSPIRE). Survey total scores are computed by calculating the mean of the sum of all item ratings then multiplying the mean by 25 to scale the score to a range from 0 to 100. Higher scores indicate a more positive perception of insulin delivery systems. Items are rated on a 5 point Likert scale ranging from 0 (strongly disagree) to 4 (strongly agree). The Adult survey has 22 items, the Teens/Adolescents survey has 17 items and the Parent survey has 21 items.</description>
        <time_frame>26 weeks</time_frame>
        <population>Scores are measured at 26 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC) in Adults</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP) in Adults</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
          <group group_id="O3">
            <title>CLC in Teens</title>
            <description>Survey response from a teen in CLC (14-18 years old)</description>
          </group>
          <group group_id="O4">
            <title>SAP in Teens</title>
            <description>Survey response from a Teen in the SAP group (ages 14-18).</description>
          </group>
          <group group_id="O5">
            <title>Parent of Teen in CLC</title>
            <description>Survey response from a parent of a teen in CLC</description>
          </group>
          <group group_id="O6">
            <title>Parent of a Teen in SAP</title>
            <description>Survey response from a parent of a teen in SAP</description>
          </group>
        </group_list>
        <measure>
          <title>INSPIRE Survey Scores</title>
          <description>The INSPIRE questionnaire assesses user expectations and experiences with Insulin Delivery Systems: Perceptions, Ideas, Reflections, Expectations (INSPIRE). Survey total scores are computed by calculating the mean of the sum of all item ratings then multiplying the mean by 25 to scale the score to a range from 0 to 100. Higher scores indicate a more positive perception of insulin delivery systems. Items are rated on a 5 point Likert scale ranging from 0 (strongly disagree) to 4 (strongly agree). The Adult survey has 22 items, the Teens/Adolescents survey has 17 items and the Parent survey has 21 items.</description>
          <population>Scores are measured at 26 weeks</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" spread="14"/>
                    <measurement group_id="O2" value="86" spread="13"/>
                    <measurement group_id="O3" value="87" spread="13"/>
                    <measurement group_id="O4" value="74" spread="12"/>
                    <measurement group_id="O5" value="87" spread="13"/>
                    <measurement group_id="O6" value="76" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>System Usability Scores (SUS)</title>
        <description>System Usability Scores (SUS)-composite score from 0 to 100 with higher scores indicate better perceived usability</description>
        <time_frame>26 weeks</time_frame>
        <population>Administered to CLC group only. Results from 26-week.</population>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
        </group_list>
        <measure>
          <title>System Usability Scores (SUS)</title>
          <description>System Usability Scores (SUS)-composite score from 0 to 100 with higher scores indicate better perceived usability</description>
          <population>Administered to CLC group only. Results from 26-week.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technology Acceptance Questionnaire</title>
        <description>Technology Acceptance Survey measures the user's perceptions regarding the burdens and the barriers associated with a technology with a higher score indicates increased technology acceptance. There total score uses 37 items with items are rated on a 5 point scale ranging from 1 (strongly disagree) to 5 (strongly agree) for total score range of 37-185.</description>
        <time_frame>26 weeks</time_frame>
        <population>Administered to CLC arm only. Result from 26-weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
        </group_list>
        <measure>
          <title>Technology Acceptance Questionnaire</title>
          <description>Technology Acceptance Survey measures the user's perceptions regarding the burdens and the barriers associated with a technology with a higher score indicates increased technology acceptance. There total score uses 37 items with items are rated on a 5 point scale ranging from 1 (strongly disagree) to 5 (strongly agree) for total score range of 37-185.</description>
          <population>Administered to CLC arm only. Result from 26-weeks.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Insulin</title>
        <description>Total Daily Insulin (units)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Insulin</title>
          <description>Total Daily Insulin (units)</description>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="27"/>
                    <measurement group_id="O2" value="51" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal:Bolus Insulin Ratio</title>
        <description>Basal:Bolus Insulin Ratio</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Basal:Bolus Insulin Ratio</title>
          <description>Basal:Bolus Insulin Ratio</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.7"/>
                    <measurement group_id="O2" value="1.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight</title>
        <description>Weight (kg)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <description>Weight (kg)</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" spread="17.0"/>
                    <measurement group_id="O2" value="76.0" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BMI</title>
        <description>Body Mass Index (BMI) kg/m^2</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index (BMI) kg/m^2</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="4.9"/>
                    <measurement group_id="O2" value="26.1" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Severe Hypoglycemia (Per Protocol)</title>
        <description>Severe hypoglycemia (per protocol)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Hypoglycemia (Per Protocol)</title>
          <description>Severe hypoglycemia (per protocol)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Diabetic Ketoacidosis (Per Protocol)</title>
        <description>Diabetic ketoacidosis (per protocol)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Diabetic Ketoacidosis (Per Protocol)</title>
          <description>Diabetic ketoacidosis (per protocol)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ketone Events Defined as Day With Ketone Level &gt;1.0 mmol/L</title>
        <description>Ketone events defined as day with ketone level &gt;1.0 mmol/L</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Ketone Events Defined as Day With Ketone Level &gt;1.0 mmol/L</title>
          <description>Ketone events defined as day with ketone level &gt;1.0 mmol/L</description>
          <units>days</units>
          <param>Number</param>
          <units_analyzed>Days</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20571"/>
                <count group_id="O2" value="10285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CGM-measured Hypoglycemic Events (&gt;15 Minutes With Glucose Concentration &lt;54 mg/dL)</title>
        <description>CGM-measured hypoglycemic events (&gt;15 minutes with glucose concentration &lt;54 mg/dL)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM-measured Hypoglycemic Events (&gt;15 Minutes With Glucose Concentration &lt;54 mg/dL)</title>
          <description>CGM-measured hypoglycemic events (&gt;15 minutes with glucose concentration &lt;54 mg/dL)</description>
          <units>events per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.1" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.2" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CGM-measured Hyperglycemic Events (&gt;15 Minutes With Glucose Concentration &gt;300 mg/dL)</title>
        <description>CGM-measured hyperglycemic events (&gt;15 minutes with glucose concentration &gt;300 mg/dL)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM-measured Hyperglycemic Events (&gt;15 Minutes With Glucose Concentration &gt;300 mg/dL)</title>
          <description>CGM-measured hyperglycemic events (&gt;15 minutes with glucose concentration &gt;300 mg/dL)</description>
          <units>events per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.4" upper_limit="2.6"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1.1" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>BG-measured Hypoglycemic Events (One BG Record &lt;54 mg/dL)</title>
        <description>BG-measured hypoglycemic events (one BG record &lt;54 mg/dL)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>BG-measured Hypoglycemic Events (One BG Record &lt;54 mg/dL)</title>
          <description>BG-measured hypoglycemic events (one BG record &lt;54 mg/dL)</description>
          <units>days</units>
          <param>Number</param>
          <units_analyzed>Days</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20571"/>
                <count group_id="O2" value="10285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>BG-measured Hyperglycemic Events (One BG Record &gt;350 mg/dL)</title>
        <description>BG-measured hyperglycemic events (one BG record &gt;350 mg/dL)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>BG-measured Hyperglycemic Events (One BG Record &gt;350 mg/dL)</title>
          <description>BG-measured hyperglycemic events (one BG record &gt;350 mg/dL)</description>
          <units>days</units>
          <param>Number</param>
          <units_analyzed>Days</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20571"/>
                <count group_id="O2" value="10285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                    <measurement group_id="O2" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Worsening of HbA1c From Baseline to 26 Weeks by &gt;0.5%</title>
        <description>Worsening of HbA1c from baseline to 26 weeks by &gt;0.5%</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Worsening of HbA1c From Baseline to 26 Weeks by &gt;0.5%</title>
          <description>Worsening of HbA1c from baseline to 26 weeks by &gt;0.5%</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Other Serious Adverse Events (SAE) and Serious Adverse Device Events (SADE)</title>
        <description>Other serious adverse events (SAE) and serious adverse device events (SADE)</description>
        <time_frame>26 weeks</time_frame>
        <population>Other Serious Adverse Events that do not include DKA or Severe Hypoglycemia</population>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Serious Adverse Events (SAE) and Serious Adverse Device Events (SADE)</title>
          <description>Other serious adverse events (SAE) and serious adverse device events (SADE)</description>
          <population>Other Serious Adverse Events that do not include DKA or Severe Hypoglycemia</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Concussion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Otitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Bypass Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Device Effects (ADE)</title>
        <description>Adverse device effects (ADE)</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC) in Adults</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP) in Adults</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Device Effects (ADE)</title>
          <description>Adverse device effects (ADE)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Unanticipated Adverse Device Effects (UADE)</title>
        <description>Unanticipated adverse device effects (UADE)</description>
        <time_frame>26 weeks</time_frame>
        <population>Study Device</population>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Unanticipated Adverse Device Effects (UADE)</title>
          <description>Unanticipated adverse device effects (UADE)</description>
          <population>Study Device</population>
          <units>Unanticipated Adverse Device Effects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With SH Events</title>
        <description>For this outcome, mean +/- SD or summary statistics appropriate to the distribution will be tabulated by treatment group</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With SH Events</title>
          <description>For this outcome, mean +/- SD or summary statistics appropriate to the distribution will be tabulated by treatment group</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>SH Event Rate Per 100 Person-years</title>
        <description>For this outcome, severe hypoglycemia event rate per 100 person-years will be calculated as a rate.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>SH Event Rate Per 100 Person-years</title>
          <description>For this outcome, severe hypoglycemia event rate per 100 person-years will be calculated as a rate.</description>
          <units>rate per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With DKA Events</title>
        <description>For this outcome, number of participants with diabetic ketoacidosis (DKA) will be tabulated.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With DKA Events</title>
          <description>For this outcome, number of participants with diabetic ketoacidosis (DKA) will be tabulated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>DKA Event Rate Per 100 Person-years</title>
        <description>For this outcome, the diabetic ketoacidosis event rate per 100 person-years will be calculated as a rate.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>DKA Event Rate Per 100 Person-years</title>
          <description>For this outcome, the diabetic ketoacidosis event rate per 100 person-years will be calculated as a rate.</description>
          <units>rate per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Any Adverse Event Rate Per 100 Person-years</title>
        <description>For this outcome, the adverse event rate per 100 person-years calculated as a rate.</description>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Control (CLC)</title>
            <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
          </group>
          <group group_id="O2">
            <title>Sensor-Augmented Pump (SAP)</title>
            <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
          </group>
        </group_list>
        <measure>
          <title>Any Adverse Event Rate Per 100 Person-years</title>
          <description>For this outcome, the adverse event rate per 100 person-years calculated as a rate.</description>
          <units>events per 100 person-yr</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From protocol entry through last study date which is approximately 26-28 weeks per participant.</time_frame>
      <desc>Definitions are the same as the clinicaltrials.gov definition. Please see clinical protocol for exclusions to adverse event collection.</desc>
      <group_list>
        <group group_id="E1">
          <title>Closed Loop Control (CLC)</title>
          <description>Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months.
t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM: Participants will use the Tandem t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 6 months at home.</description>
        </group>
        <group group_id="E2">
          <title>Sensor-Augmented Pump (SAP)</title>
          <description>Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
Sensor-augmented pump (SAP): Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Bypass Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia or ketosis events without meeting criteria for Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sue Brown, MD</name_or_title>
      <organization>University of Virginia</organization>
      <phone>434-962-0602</phone>
      <email>sab2f@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

